Why Is HIMS & HERS HEALTH I A (HIMS) Stock Down Today?
By the Top Tier Newswire AI Desk · November 10, 2026 at 11:24 AM ET · reviewed against 42 wire stories
HIMS & HERS HEALTH I A (HIMS) is down -16.80% in the latest session. Our newswire has captured 42 stories on HIMS across 20 sources in the last 36 hours, with AI sentiment reading mixed (avg 43/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Hims & Hers Health shares fell 16.80% to close at $19.09, marking a new 52-week low. The primary driver was a quarterly earnings miss and a reduction in revenue guidance, which intensified concerns over subscriber retention in the competitive weight-loss drug market.
What Happened
The company reported third-quarter revenue of $890.3 million and an EPS of -$0.14, both of which fell short of analyst estimates. Management narrowed its 2026 revenue guidance to a range of $3.13 billion to $3.15 billion. Jefferies warned that a dynamic GLP-1 environment would continue to cause volatility in subscriptions, noting that the stock is hitting seven-month lows. The CFO stated on the earnings call that the company intentionally paced Q3 marketing spend on weight-loss treatments and expects the Eli Lilly partnership to improve platform retention. Additionally, the company announced plans to launch a Peptides+ offering later this month, featuring glutathione, NAD, sermorelin, and B-12, while BPC-157 and TB-500 await regulatory approval.
What The Data Shows
The stock opened at $22.52, a 1.8% gap down from the prior close, and traded as low as $19.00 at 11:20 AM ET. Volume reached 26.9 million shares, which is 2.3 times the three-month daily average. The company has a market cap of $6.1 billion and remains unprofitable with a trailing twelve-month EPS of -0.62. Revenue grew 28.0% over the same period, but the net margin stands at -5.5%. The stock has a beta of 2.50 and a 52-week range of $13.74 to $42.70. Over the last eight sessions, the stock declined 22.7%. Unusual options activity included 23 notable prints with $5.5 million in call premium versus $2.7 million in put premium. Insider activity shows 14 sells totaling $6.0 million in the last 90 days, including recent sales by General Counsel Boughton Soleil and CFO Okupe Oluyemi.
What To Watch
Analysts have revised their forecasts following the results. Evercore ISI Group maintains an In-Line rating with a price target of $27, while Needham maintains a Buy rating with a lowered price target of $32. Investors will monitor coverage breadth and how the company executes its new product launches against the backdrop of heightened competition in the healthcare sector.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
HIMS · Nov 10 session (5-min) · -17.18% vs prior close · updated 8:51 PM ETAI sentiment, last 36h · averaged over 42 stories · 43/100 bearish
The headlines behind the move
Story flow · 8 stories on the wire, last 36h · hover or tap a dot for the headline
3d agoStocktwits NewsBEARISH 34Analyst
HIMS May See Heightened ‘Gyrations’ As Weight-Loss Drug Trends Fuel Subscriber Uncertainty, Jefferies Warns – Stock Hits 7-Month Lows
Jefferies said a ‘dynamic GLP-1 environment’ would continue to cause volatility in Hims & Hers’ subscriptions
3d agoSeeking AlphaBEARISH 24Earnings
Hims & Hers Health slides 14% after earnings miss, guidance cut
Hims & Hers shares fall 14% after Q3 revenue of $890.3 million and EPS of -$0.14 miss estimates; 2026 revenue guidance narrows to $3.13B-$3.15B.
3d agoTipRanksBEARISH 42Analyst
Hims & Hers (HIMS) Needs Better Profits to Justify Its Price
Hims & Hers ($HIMS) needs better profits to justify its price, in my view. The online healthcare platform grew Q3 revenue 49%, but cash generation weakened. CEO...
3d agoSeeking AlphaBEARISH 34Analyst
Hims & Hers: Why I'm Not Buying Back Yet (Rating Downgrade)
Hims & Hers: 22.7x adjusted EBITDA looks costly with gross margin at 57.2%; a 233-million-share scenario implies 46% downside to $12.45. Click for more on HIMS stock.
3d agoSeeking AlphaBULLISH 58Product/PR
Hims & Hers teases November launch of Peptides+
Hims & Hers plans to launch Peptides+ offering later this month with glutathione, NAD, sermorelin, and B-12; BPC-157 and TB-500 await regulatory nod. Read more here.
Healthcare stocks were mixed pre-bell Tuesday, with the State Street Health Care Select Sector SPDR ETF (XLV.NaE) 0.2% higher and the iShares Biotechnology ETF down 0.2%. Hims & Hers Health (HIMS.NaE) shares were down more than 2% after the company reported that it swung to a Q3 loss and trimmed the high end of its 2026 revenue guidance range.
Hims & Hers posted a surprise Q3 2026 earnings loss and cut its forecast - qz.com
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →